BioSpace News Archive

MacroGenics, Inc. announced that its partner, Gilead Sciences, Inc., nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 28,300 shares, and restricted stock units covering an aggregate of 19,900 shares, of BioCryst common stock.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the full launch of Axoguard HA+ Nerve Protector.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced treatment of the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

Krystal Biotech, Inc. announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for KB408 for the treatment of alpha-1 antitrypsin deficiency.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that the Company expects to report positive adjusted EBITDA1 for its third quarter ended August 31, 2023.

Tonix Pharmaceuticals Holding Corp. announced topline results from the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long COVID.

Milestone Pharmaceuticals Inc. announced that members of its management team will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 9:00 a.m. ET.

CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences.